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Abstract
Cancer cells adopt glycolysis as the major source of metabolic energy production for fast cell growth. The HIF-1-induced
PFKFB3 plays a key role in this adaptation by elevating the concentration of Fru-2,6-BP, the most potent glycolysis
stimulator. As this metabolic conversion has been suggested to be a hallmark of cancer, PFKFB3 has emerged as a novel
target for cancer chemotherapy. Here, we report that a small molecular inhibitor, N4A, was identified as an initial lead
compound for PFKFB3 inhibitor with therapeutic potential. In an attempt to improve its potency, we determined the crystal
structure of the PFKFB3NN4A complex to 2.4 A ˚ resolution and, exploiting the resulting molecular information, attained the
more potent YN1. When tested on cultured cancer cells, both N4A and YN1 inhibited PFKFB3, suppressing the Fru-2,6-BP
level, which in turn suppressed glycolysis and, ultimately, led to cell death. This study validates PFKFB3 as a target for new
cancer therapies and provides a framework for future development efforts.
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Introduction
Unlike normal cells, cancer cells have been noted to shift their
energy metabolism toward glycolysis [1]. This phenomenon,
originally termed the Warburg effect and this transition allows
cancer cells to satisfy increased biosynthetic requirements for
biomass and energy [2,3]. Studies have consistently shown an
abnormally high glycolytic rate in a wide spectrum of human
cancers but the causative mechanisms responsible for this
metabolic adaptation remain poorly understood [4,5]. Among
the possible mechanisms, mitochondrial respiratory defects and
hypoxia in the tumor microenvironment are attributed as two
major factors for the Warburg effect [6,7,8]. Despite the
complexity and obscurity of underlying mechanisms responsible
for the Warburg effect, the metabolic consequences are a
consistent transformation toward glycolysis as the major source
of ATP production [4,9]. This metabolic abnormality of cancer
cells provides abiochemical basis to preferentially suppress
progression of malignant cells by selective inhibition of glycolysis
[10,11,12].
In the glycolysis pathway, phosphofructokinase-1(PFK-1) cata-
lyzes the major rate-limiting step that converts fructose-6-
phosphate (Fru-6-P) to fructose-1, 6-bisphosphate (Fru-1, 6-BP)
and is allosterically regulated by fructose-2,6-bisphosphate (Fru-
2,6-BP) [13,14]. Under abundant energy supply, high levels of
ATP strongly inhibit PFK-1 activity; however, Fru-2,6-BP can
override this inhibitory effect and enhance glucose uptake and
glycolytic flux [15]. Not surprisingly, Fru-2,6-BP synthesis is up-
regulated in many cancer cell lines, suggesting that selective
depletion of intracellular Fru-2,6-BP in cancer cells may
potentially be used to impede glycolytic flux and suppress
malignant cell survival and progression [16,17,18].
A family of bifunctional enzymes, 6-phosphofructo-2-kinase/
fructose-2,6-bisphosphatases (PFKFB1–4), are responsible for the
intracellular levels of Fru-2,6-BP [18,19,20]. Among these
isozymes, PFKFB3 is dominantly over-expressed in thyroid,
breast, colon, prostatic, and ovarian tumor cell lines [18,21,22].
Recent studies have shown that induction of PFKFB3 expression
by HIF-1 under hypoxic condition is followed by increased
invasive potential and resistance to chemotherapies [21,23]. Taken
together, these studies suggest PFKFB3 is a potential target for a
new class of anti-neoplastic agents that prevent onset of the cancer-
specific glycolysis by inhibiting the Fru-2,6-BP surge and,
eventually, induce death of cancer cells. Accordingly, inhibition
of PFKFB3 as a therapeutic strategy for cancer has been suggested
[22].
Despite the potential merits, exploitation of PFKFB3 for cancer
therapy has remained poor. Clem et al (2008) reported a pyridinyl-
containing compound as a possible PFKFB3 inhibitor, based on
the receptor structure predicted from that of PFKFB4 [24].
Although promising, inhibitors based on structures other than the
true PFKFB3 enzyme may lack specificity and limit strategic
improvement of inhibitor potency. We were able to overcome
such an inborn defect by engaging in the structural studies of
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identified N4A as a novel competitive inhibitor and tested its
inhibitory effect on PFKFB3 activity. To understand the molecular
mechanism of inhibitor-recognition by PFKFB3, we determined
the structure of the PFKFB3 in complex with N4A.Guided by the
structural basis for inhibitor binding; we were then able to
optimize N4A, using similarity search and computational
evaluation, resulting in a follow-up lead compound with a 5-fold
improvement in potency.
In addition to the molecular mechanism of PFKFB3 inhibition
and inhibitor improvement, we also investigated the inhibition of
Fru-2,6-BP production and glycolysis in HeLa cells by the
PFKFB3 inhibitor treatment. The novel PFKFB3 inhibitors,
N4A and YN1 reduced the Fru-2,6-BP levels and glycolytic flux,
resulting in growth inhibition of tumor cells and massive cell death.
These results provide not only evidence that validates targeting of
PFKFB3 but also the first direct structural insight into the protein
inhibitor interactions, establishing a foundation for structure-
assisted optimization and development of novel PFKFB3 inhib-
itors as chemotherapeutic agents for cancer.
Results
Overall strategy for inhibitor screening and improvement
A schematic flow diagram describing our strategy adopted for
discovery and improvement of the PFKFB3 inhibitors is shown in
Figure 1. Candidates for a lead compound were selected from
computational screening using the crystal structure of PFKFB3
which we have previously determined to 2.1 A ˚ resolution [25] was
used as molecular sieve of screening(a). The resulting hit
compounds from this molecular sieve were evaluated by enzymatic
inhibition assay and compounds with the highest inhibition activity
were selected as lead molecules after consideration of drug-
likeliness (b). Next, detailed kinetic properties were characterized
(c) and the biological effects on human adenocarcinoma cells were
investigated by measuring glycolytic flux, growth inhibition, and
cell death (d). To understand the molecular basis of the inhibition
of PFKFB3, X-ray crystallographic structure analysis of the
PFKFB3Ninhibitor complex was carried out (e). Based on the
molecular information gained from Step (e), we performed a
search for novel derivative compounds with improved potency,
using the lead compound as a template (f). The resulting
compounds from this similarity search were evaluated through
computational docking using FlexX [26] (a) and the best
optimized compound was passed through this selection process
again. Through iterative cycles of these processes, we were able to
obtain a compound with inhibitory activity orders of magnitude
above the initial lead and which exhibits potent PFKFB3
inhibition in vitro.
Inhibitor Screening and Binding Properties
During our previous study, several compounds capable of
binding to the Fru-6-P pocket of PFKFB3 were identified from
virtual screening. To confirm the inhibitory activities and to
eliminate false positives from these drug candidates, PFKFB3
inhibition was tested at 10 mM each of the compounds (Figure 2A).
To prevent non-specific inhibition caused by random hydrophobic
interactions between inhibitor and protein, a same test was
performed in the presence of 0.1% Tween-20. Among the tested
compounds, ZINC04887558 (N4A, 5, 6, 7, 8-tetrahydroxy-2-(4-
hydroxyphenyl) chromen-4-one) inhibited enzyme activity greater
than 65% under substrate-saturating conditions and this inhibition
was not affected by the presence of Tween-20. We selected N4A as
an initial ‘lead’ (Figure 2B). The subsequent kinetic study revealed
that N4A inhibits PFKFB3 with an IC50 value of2.9760.16 mM
(Table 1). A steady state inhibition study showed that N4A inhibits
PFKFB3 as a competitive inhibitor against Fru-6-Pwith a Ki of
1.2960.26 mM, as expected from virtual screening and as
demonstrated in a Lineweaver–Burk plot (Figure 2C).
Improving the inhibition efficacy of the lead compound, N4A,
by structure-guided optimization is an important goal of this study.
As the details will be discussed in the following sections, only a
brief end result is introduced here for early comparisons. Two
additional N4A inhibitors, YN1 (7, 8-dihydroxy-3-(4-hydroxyphe-
nyl) chromen-4-one) and YZ9 (ethyl 7-hydroxy-2-oxochromene-3-
carboxylate) (Figure 2B )have been obtained using structure-
guided optimization. As summarized in Table 1, YN1 exhibit-
sIC50=0.67 mM and Ki=0.2460.03 mM, showing a 5-fold
increase in inhibition. Compound YZ9 shows even greater
inhibition—one order of magnitude over the starting lead, N4A.
All the tested compounds are soluble in various aqueous solutions
up to 50 mM ranges in the presence of ,1% dimethyl sulfoxide
(DMSO).
The lead compound, N4A, and a derivative, YN1, were tested
for their inhibitory effects on other human PFKFB isoforms. The
inhibitors had a stronger effect on PFKFB3 than on other PFKFB
isoforms. At twice the IC50 for PFKFB3 where PFKFB3 was over
80% inhibited, N4A exhibits less than 50% inhibition and YN1
shows less than 40% inhibition on PFKFB1, PFKFB2 and
PFKFB4 (Figure 2E). N4A and YN1 are comparatively selective
inhibitors of PFKFB3. Improving the isoform specificity must be
the main goal of next stage optimization and such efforts are being
made.
Effects of N4A and YN1 on the Fru-2,6-BP levels,
glycolysis, and cell growth
We next investigated effects of applying the N4A and
YN1inhibitors to live HeLa cells. Inhibition of PFKFB3 is
expected to cause a decrease in the levels of Fru-2,6-BP in HeLa
cells. After an 8 hour exposure to N4A and YN1, Fru-2,6-BP were
reduced approximately 20%; after a 48-hour exposure, Fru-2,6-BP
was reduced over 40% (Figure 3A). Down-regulation of the Fru-
2,6-BP levels by N4A and YN1 was accompanied by decreased
glycolysis, as expected. The decrease in the Fru-2,6-BP levels
Figure 1. Flowchart showing the overall strategy used for
development of the PFKFB3 inhibitors.
doi:10.1371/journal.pone.0024179.g001
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production, which was reflected by a greater than 30% decrease in
lactate secretions. Taken together, these data suggest N4A and
YN1 inhibit PFKFB3 resulting in suppression of glycolysis
(Figure 3B).
Increased Fru-2,6-BP levels preceded by increased glycolysis
often accompanies the proliferation of transformed cells, including
cancer cells [3]. We examined the effect of the PFKFB3 inhibitors,
N4A and YN1, on the proliferation rate of human adenocarci-
noma cells. Treatments with 25 mM each of N4A and YN1 caused
70% and over 90% reductions, respectively, in cell proliferation,
when compared to unexposed cells (Figure 3C). The results of cell
growth inhibition assays consistently confirmed that inhibition of
PFKFB3 by N4A and YN1 suppresses cellular energy metabolism
and, ultimately, cell growth and that YN1 is a more potent
inhibitor with a GI50 of 8.260.8 mM compared with N4A
(GI50=14.261.5 mM) (Table 1). N4A and YN1 were also able
to inhibit soft agar colony formation in HeLa cells (Figure 4).
HeLa cells were plated in soft agar with different concentrations of
N4A or YN1 and grown for 3 weeks to allow colony formation.
Both compounds significantly inhibited colony formation at 25, 50
and 100 mM. Colony formation was inhibited by 64% and 79% in
the presence of 25 mM N4A and YN1, respectively.
To further investigate the mechanism responsible for the anti-
proliferative effect of the PFKFB3 inhibitors, flow-cytometric
analysis of cell death was performed. The results indicate that N4A
and YN1 induced both apoptotic and necrotic cell death. This
mixed pattern is related to the nature of apoptosis, which, unlike
necrosis, is an ATP-dependent process [27,28]. Cell death induced
by the PFKFB3 inhibitors should correlate with their ability to
deplete cellular ATP and depletion of ATP favors death by
necrosis as previously speculated [11,27,28]. Our data supports
this argument: at a relatively low concentration (25 mM) of N4A or
YN1, an environment in which depletion of cellular energy
depletion is moderate, cells were found to be prone to apoptosis,
whereas, at higher concentrations (50 mM) of inhibitors, death by
necrosis was significantly increased due to insufficient cellular
energy to support the apoptotic process (Figure 5).
Structure of the PFKFB3NN4A complex
We wished to use the N4A inhibitor as a lead for structure-
guided optimization of further inhibitors. To facilitate this task, it
was necessary to determine the molecular characteristics of N4A
binding to PFKFB3 by crystallizing human PFKFB3 in the
presence of N4A. We determined the structure of this complex to
2.4 A ˚ resolution by a method of molecular replacement using the
first PFKFB3 structure (PDB code: 2AXN) as a search model [29].
An |Fo|2|Fc| omit map enabled unambiguous placement of
N4A into theFru-6-P binding pocket of the kinase domain of
PFKFB3 (Figure 6A). The N4A located at the Fru-6-P pocket
could be superimposed onto the Fru-6-P modeled in the structure
of PFKFB3 in a ternary complex with AMPPCP and Fru-6-P
(PDB code: 2DWP) [29]. This structure provides clear evidence,
supporting the kinetic observations that N4A competes with Fru-6-
P for the same binding pocket in PFKFB3 (Figure 6B, C, D). As
shown in Figure 6B and D, N4A is anchored to the Fru-6-P pocket
via hydrogen bonds with Arg74, Asp124, Thr126, and Arg132.
The phenol moiety of N4A is unfavorably located in the pocket
where the 6-phosphate moiety of Fru-6-P interacts through a
hydrogen bond with Arg132 and results in Arg132 adopting a
different conformation in the N4A complex. The chromone
moiety of N4A occupies the same position as the fructose moiety.
Here, two of N4A’s hydroxyl groups (OAF and OAA) mimic the
hydrogen-bonding pattern of the hydroxyl groups at the C3 and
C4 positions of the fructose moiety. The binding competence of
N4A is further strengthened by a number of water-mediated
hydrogen bonds between the hydroxyl group of the N4A with
Thr48, Arg98, Asp124, Thr126, and Tyr193 and the conforma-
tional changes induced upon the binding (Figure 6C). The protein
ligand interactions are summarized in Table 2.
When compared with PFKFB3 complexed with AMPPCP and
Fru-6-P (PDB code: 2DWP), the N4A-PFKFB3 complex induces
no significant difference in global structure. However, the
differences around the F-6-P binding pocket were evident as
shown in Figure 6D. Upon N4A binding, the Arg132 side chain
swings out about 3.5 A ˚ from the position for Fru-6-P site, offering
space to accommodate N4A. As a consequence, Glu131 in the
same helix moves toward the F-6-P pocket by ,2A ˚. The
guanidine group of Arg75 moved 1.5 A ˚ toward the inhibitor from
its original position, implying that the closer positioning of Arg75
stabilizes inhibitor binding. The phenol group on Tyr424 is tilted
toward N4A due to the repositioning of water molecules near
Tyr424 upon N4A binding. These local conformational changes in
the F-6-P pocket affect the mobile ATP loop, especially a turn
(residues 168–180), which flips into the F-6-P pocket, a
displacement of over 2 A ˚ (data not shown).
YN1 and YZ9 from the exploration of N4A scaffold
YN1. To increase the inhibition potency of N4A, firstly, we
performed a similarity search using N4A as a template and with a
defined Tanimoto coefficient $0.9 [30]. The selected molecules
from the entire NCI Database were evaluated via computational
docking [26] and, as a result, ZINC06093399 (YN1) was predicted
Table 1. The kinetic and biological properties of the PFKFB3
inhibitors.
Inhibitor IC50 [mM] Ki [mM] Inhibition GI50[mM]
N4A 2.9760.16 1.2960.26 Competitive
to Fru-6-P
14.261.5
YN1 0.6760.08 0.2460.03 Competitive
to Fru-6-P
8.260.8




Figure 2. Experimental evaluation of the hit compounds. (A) Inhibition potencies of the candidate compounds. The magnitudes of inhibition
by compounds at 10 mM each are measured through the enzyme assay and presented as percentiles against the control (%). A same experiment was
also performed in the presence of 0.1% Tween-20 (&), to eliminate false positives caused by nonspecific hydrophobic interactions. (B) Structures of
the PFKFB3 inhibitors. (C) Lineweaver-Burk plots showing the competitive inhibition by N4A against Fru-6-P. The inhibitor concentrations used were:
0 mM( &), 1 mM( #), 2 mM( m), and 3 mM( %) of N4A. They are also labeled next to individual plots. (D) Lineweaver-Burk plots showing the
competitive inhibition by YN1 against Fru-6-P. The inhibitor concentrations used were: 0 mM( &), 1 mM( #), 2 mM( m), and 3 mM( %) of N4A. (e)
Selectivity of N4A and YN1 on PFKFB isoforms. Results are expressed as percent inhibition at twice the IC50 concentration against PFKFB3
(N4A=6 mM, YN1=1.3 mM).
doi:10.1371/journal.pone.0024179.g002
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YN1, purchased from CHESS GmbH, was tested for its inhibition
potency and kinetic properties and demonstrated a 5-fold increase
in PFKFB3 inhibition compared to N4A (Table 1).
In order to determine the molecular basis for the increased
inhibition potency of YN1, the crystal structure of the PFKFB3 in
complex with YN1 was also determined but at the modest
resolution of 3.3 A ˚. Because of this resolution limit, the structure
refinement was performed using only rigid body and B-group
refinement, taking the whole protein structure of the N4A complex
as a rigid body. Similar to N4A, YN1 binds to theFru-6-P binding
pocket as clearly shown in an omit |Fo|2|Fc| electron density
maps (Figure 6E). In addition, like N4A, YN1 interacts with
PFKFB3 by occupying the Fru-6-P pocket. However, the electron
density for YN1 is better modeled by flipping YN1 180u in respect
to its short axis, compared to the orientation of N4A, resulting in
the phenol moiety of YN1 being positioned towards the site
occupied by the fructose moiety of Fru-6-P rather than the site of
the phosphate of Fru-6-P. This orientation may be a consequence
of the substitution of benzenediol for benzenetetrol in the
chromone moiety of the two inhibitors. The additional hydroxyl
groups on the chromone moiety of N4A perhaps cannot be
accommodated at the binding site for the 6-phosphate moiety of
Fru-6-P. However, YN1 with a loss of two hydroxyl groups in the
same chromone moiety is able to bind to the site in a direction
opposite that of N4A. Then, the chromone moiety of YN1 is
inserted between Val70 and Phe87 gaining hydrophobic interac-
tions and a Cation-p interaction with Arg98, while its phenol
moiety gains a Cation-p interaction with Arg189 and a hydrogen
bond with Arg75 (Table 2). Water mediated interactions, similar
to those observed in the N4A complex, very likely contribute to the
YN1 interaction, although the resolution limit did not allow for the
modeling of water in the YN1 complex.
Certainly, our observations regarding YN1 require supporting
evidence from high resolution X-ray data. Nevertheless, because
only the position of YN1 was refined inside the N4A binding
pocket as a rigid body, this new binding mode observed for YN1 is
significant. Comparison of the binding modes of N4A and YN1
Figure 3. The effects of the PFKFB3 inhibitors on the Fru-2,6-BP levels, the lactate secretions, and the cell growths. The Fru-2,6-BP
levels (A) and the levels of secreted lactate (B) were determined enzymatically at time points 0, 4, 8, 12, 24, or 48 hours after the inhibitor treatments
of HeLa cells. The results were normalized to the sample protein concentrations and expressed as a ratio to the value of vehicle-treated. Data are
means 6 S.E.M. from at least three experiments. Time-dependent effects of 25 mM each of N4A (line with diamond) and YN1 (dotted line with hollow
square) on the cellular Fru-2,6-BP levels (A) and the lactate secretions (B) are shown. (C) Growth inhibition by N4A , YN1, and YZ9 on HeLa and T47D
cells. Cell numbers were assayed over 36 hours by the trypan blue counting or XTT assay. Data points are expressed as % cell growth of control
containing vehicle against logarithmic scale of inhibitor concentrations. Error bars stand for intraexperimental replicates standard deviation.
doi:10.1371/journal.pone.0024179.g003
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Arg residues present, is surprisingly generous to the binding of
compounds with hydrophobic rings. It is likely that the pocket
takes advantage of Cation-p interactions as seen in other structures
[31] and water-mediated hydrogen bonds. The higher potency of
YN1 compared to N4A and the apparent difference in binding
modes between the two compounds, taken together, suggest that
compounds containing a chromone moiety with fewer hydroxyl
groups will be more potent than either N4A or YN1.
YZ9. Using a strategy similar to that used to find YN1, we
identified YZ9. Using the same biological test routine, we
determined that YZ9 inhibited PFKFB3 with an IC50 of
0.183 mM, and acted as a competitive inhibitor against Fru-6-P
with a Ki of 0.094 mM (Table 1). YZ9 also inhibited the cell
growth with a GI50 of 2.7 mM. Further characterization of YZ9 is
on-going.
Discussion
Suppression of anaerobic glycolysis has been suggested as a
promising strategy for the development of chemotherapeutic
agents for cancer, because tumor cells exhibit an abnormally high
Figure 4. Treatment of HeLa cells with N4A and YN1 inhibits soft agar colony formation. (A) Anchorage-independent cell growth in soft
agar. HeLa cells were grown in soft agar for 21 days in the presence of the indicated concentrations of N4A and YN1 respectively (206). (B) Statistical
analysis of the experiment. Columns, mean (n=5); bars, SD.
doi:10.1371/journal.pone.0024179.g004
Small Molecule PFKFB3 Inhibitors
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24179Small Molecule PFKFB3 Inhibitors
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24179glycolytic rate even in the presence of oxygen [10,11,12]. The rate
of glycolysis is regulated by the cellular concentration of Fru-2,6-
BP, a potent stimulator of glycolysis [13,14,15]. Recent studies
invariably show that Fru-2,6-BP production is increased in
transformed cell lines due to the expression of PFKFB3, the
hypoxia-inducible isoform of the 6-phosphofructo-2-kinase/fruc-
tose-2,6-bisphosphatases, that catalyzes the synthesis of Fru-2,6-BP
at least ten times greater rate than other isoforms [17,18,20,21,22].
Accordingly, it has been hypothesized that inhibition of PFKFB3
would deprive tumor cells of energy sources necessary for
proliferation and growth [12,22].
In this report, we were able to introduce a potent competitive
inhibitor of PFKFB3, N4A with an IC50 of 2.97 mM. The inhibitor
also shows a stronger effect on PFKFB3 than on other PFKFB
isoforms. Despite high homology between PFKFB isoforms, the
inhibitor has much higher specificity for PFKFB3 than we
thought. As a result of proper targeting, the PFKFB3 inhibitor
reduced the Fru-2,6-BP level and glycolytic rate in cell, ultimately,
leading to tumor growth inhibition and massive cell death. The
cell death induced by the inhibitor involves both apoptosis and
necrosis. Our observation is coincident with previous reports that
depletion of cellular energy tends to cause necrotic cell death,
because apoptosis is an energy requiring process [11,27,28].
Supporting this idea, we found apoptotic cell death was primarily
observed at a relatively low inhibitor concentration (25 mM),
which would produce only moderate energy depletion. On the
Figure 6. Structure of PFKFB3 in complex with inhibitors. (A) Ribbon diagram of the crystal structure of the PFKFB3NN4A complex. N4A bound
to the PFKFB3 Fru-6-P site in the 2-Kase catalytic pocket is shown with a concomitant |Fo|2|Fc| omit map at a 2.5 level. The Fru-6-P bound to the 2-
Pase domain is also shown in gray for comparison. (B)The interactions between N4A and PFKFB3 are shown. Hydrogen bonds are shown as yellow
dotted lines and a Cation-p interaction is represented by a red broken line. (C) The water-mediated hydrogen bonds between PFKFB3 and N4A are
shown in yellow dotted lines. (D)Inhibitor-induced local conformational changes around the N4A binding groove. Comparison of the structures of
the PFKFB3NAMPPCPNFru-6-P complex (dark gray) and the PFKFB3NN4A complex (color) was made. (E)YN1 bound to the same pocket with a |Fo|2|Fc|
omit map at 2.5 level is shown. Hydrogen bonds between YN1 and PFKFB3 are shown as yellow dotted lines and Cation-p interactions as red broken
lines.
doi:10.1371/journal.pone.0024179.g006
Figure 5. Induction of cell death in HeLa cells by the PFKFB3 inhibitors, N4A and YN1. The cells were treated with two different
concentrations of inhibitors, 25 mM and 50 mM. (A) Induced cell death at two different concentrations of N4A was measured by flow cytometry after
double staining with Annexin V and PI. (B) Quantitation of the flow-cytometric data (mean 6 SD) showing a dose-related effect of N4A. (C)
Cytograms of YN- induced cell death and (D) quantitation of the flow-cytometric data.
doi:10.1371/journal.pone.0024179.g005
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cantly increased both necrosis and apoptosis, leading to an
insufficient energy state where the apoptotic process is not favored.
Although N4A and YN1 show comparatively selective PFKFB3
inhibition between the PFKFB isoforms, the anti-proliferative
effect of the inhibitors on cancer cells cannot be solely ascribed to
the inhibition of PFKFB3 kinase activity. However, the develop-
ment of N4A and YN1 is a first step toward the goal to obtain
specific PFKFB3 inhibitors possessing high selectivity and low
general toxicity.
Determination of protein structures in complex with an
inhibitor is necessary to obtain mechanisms for inhibitor
recognition at the molecular level and to provide an opportunity
to identify alternative molecules with higher potency [32,33].
Understanding the molecular basis for interactions between a
potential drug molecule and its target protein is a critical step in
successful drug development [33]. We were able to determine the
first molecular structure of PFKFB3 in complex with an inhibitor,
and then use this structural data to improve potency of the
inhibitor. The crystal structures of PFKFB3 in complex with N4A
revealed information on inhibitor binding at the molecular level.
The crystal structure with YN1 provided an insight into alternative
bindings of similar compounds, despite the moderate resolution.
The two together provided the blue print of new compounds and
rational guidelines for design of novel PFKFB3 inhibitors.
Although YN1 is a derivative of the lead compound N4A and
the binding modes of the two inhibitors are in approximately the
same plane, it appears, even at the modest resolution of the YN1
complex, that the interactions of these two compounds with
PFKFB3 are quite different. The difference of orientations within
the same Fru-6-P plane is likely the consequence of YN1 having a
less bulky chromone moiety (two fewer hydroxyl groups compared
to N4A). The new binding mode observed for YN1 results in new
hydrophobic interactions and the addition of Cation-p interac-
tions, which together compensate for the loss of hydroxyl groups,
which participated in hydrogen bond in the N4A complex, and
appear to support the higher inhibitory activity of YN1. It is
noteworthy that our inhibitors with no negatively charged group
efficiently target the Fru-6-P pocket, which is populated with
positively charged residues. The accompanied energy penalty for
such bindings is likely to be paid by increases in the Cation-p
interactions. This speculation was tested with the third compound
YZ9, which showed the inhibition potency increased by an order
of magnitude, although detailed characterizations including a
structural analysis have yet to be performed.
Our data suggested the approach taken in this report will enable
the rational design of PFKFB3 inhibitors, which will have a higher
specificity by targeting the Fru-6-P site instead of targeting the
ATP site since the ATP site fold is shared by thousands of
other kinases [34,35]. This report provides a framework for the
rational development of the PFKFB3 inhibitors as new cancer
therapeutics.
Materials and Methods
2-kase assay and kinetic analysis
To determine steady-state initial reaction rates, the 2-Kase
reactions were performed first and the Fru-2,6-BP produced was
measured by a conventional enzyme-coupled kinetics assay as
described previously [29,36]. Initial rates of decrease in absor-
bance (Abs) at 340 nm were corrected with the rate of the control
reaction in which no Fru-2,6-BP was present. Negative controls were
carried out in the absence of enzyme and positive controls indicate the
reaction in the presence of enzyme without inhibitor compounds. The
percentage of Inhibitory activity was calculated according to the
formula: % inhibition=1006[12(Absnegativecontrol2Abscompound)/
(Absnegativecontrol2Abspositivecontrol)]. IC50 values were determined in
quadruplicate. For the kinetic studies, concentrations of one of
Table 2. Interactions between the inhibitors and PFKFB3.
Protein residue Water Inhibitor N4A Type of interaction Distance (A ˚)
Arg74 NE O4 Hydrogen bond 2.9
NH2 O5 Hydrogen bond 3.0
Asp124 O O8 Hydrogen bond 3.5
Thr126 OG1 O1 Hydrogen bond 3.3
Arg132 NE O49 Hydrogen bond 2.2
Arg98 Phenol moiety Cation-p interaction 5
Thr48 OG1 HOH38 3.3
Asp124 OD1 HOH38 3.2
HOH38 O7 Water mediated interaction 2.3
Thr126 OG1 HOH97 3.5
Tyr193 OH HOH97 2.2
HOH97 O1 Water mediated interaction 2.6
Protein residue Water Inhibitor YN1 Type of interaction Distance (A ˚)
Arg75 NH1 O49 Hydrogen bond 3.5
Arg98 NE O8 Hydrogen bond 3.2
Thr126 OG1 O4 Hydrogen bond 3.5
Arg98 Chromone moiety Cation-p interaction 4
Arg189 Phenol moiety Cation-p interaction 3.5
doi:10.1371/journal.pone.0024179.t002
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340 nm was measured. The inhibition patterns were analyzed
using the program written by Cleland, in which Ki is the
dissociation constants for the inhibitor from enzyme-inhibitor
complex [37]. For Selectivity studies, the 2-Kase assays were
performed first and the F-2,6-P2 produced was measured by an
enzyme coupled kinetics assay as described above. The His6-
tagged PFKFB isoforms, PFKFB1, PFKFB2, and PFKFB4 were
expressed in Escherichia coli C41(DE3) and purified using Ni-
NTA affinity columns.
Similarity Search
Similarity searches, using N4A or YN1 as a template, were
performed using the NCI Enhanced Web Browser (http://129.43.
27.140/ncidb2/) with a defined Tanimoto coefficient $0.9 [30].
The entire Open NCI Database was used using Tanimoto index
and the selected compounds were consequently evaluated through
docking. Docking was performed on the structure of the
PFKFB3NADPNF6P complex (PDB code: 2AXN), using FlexX,
after stripping the ligands [26,29]. The docking calculations were
performed with an active-site encompassing a sphere of 15 A ˚
around the reference structure position in the PDB file. The high
rank compounds were purchased from CHESS GmbH (Germany)
or from other suppliers.
Preparation and crystallization of PFKFB3
Preparation of the protein sample and its crystallization was
performed as described [25]. The 66His-tagged human PFKFB3
was expressed in Escherichia coli BL21(DE3) pLysS and purified
using Ni-NTA affinity columns and, subsequently, Mono Q anion-
exchange chromatography. The resulting pureprotein was kept, after
concentrating to 8 mg ml
21 protein, in 20 mM TrisNHCl (pH 8.0),
10 mM NaPi, 0 . 0 5m M E D T A , 5m M b-mercaptoethanol, 5%
glycerol, 0.2 mM Fru-6-P. Crystals were prepared by the sitting-
drop, vapor-diffusion method with a 1:1 (v/v) mixture of the protein
sample with a reservoir solution of 50 mM HEPES pH 7, 7–20%
DMSO, 0.2–1.5 mMof inhibitors, and 7% (w/v) polyethylene glycol
4000. Crystals with a size of 0.2 mm60.1 mm60.2 mm grew in two
to three weeks.
Cell culture
HeLa and T47D cell lines were cultured in a 10% CO2
humidified atmosphere at 37uC as exponentially growing
monolayers in Dulbecco’s modified Eagle’s medium (DMEM)
with glutamax (Invitrogen), supplemented with 10% fetal calf
serum (Invitrogen) and penicillin/streptomycin (100 U/ml and
100 mg/ml). The human cervical carcinoma cell line, HeLa, was
kindly provided by Dr. J. Kim (Louisiana State University) and the
human breast carcinoma cell line, T47D, was obtained from the
American Type Culture Collection (Manassas, VA).
Metabolite determination
HeLa cells were plated at a density of 2.5610
5 in a 6-well plate
in DMEM containing 10% FCS. The media were replaced with
fresh DMEM containing either vehicle (dimethyl sulfoxide) or
25 mM of inhibitor the following day. After 0, 4, 8, 12, 24, or
48 hours of incubation with each inhibitor, media samples were
collected for measuring the lactate secretion levels using a lactate
oxidase-based assay kit (Sigma-Aldrich) and the lactate concen-
tration was normalized to the total cellular protein concentration.
The Fru-2,6-BP level was determined with collected cells at times
of 0, 4,8,12,24, or 48 hours after the treatment, using the method
described previously [36].
Cell Proliferation/Survival Assays
Cell growth inhibition was determined by an XTT-based in-
vitro toxicology assay (Sigma-Aldrich) or trypan blue staining.
Cells were plated at a density of 3.5610
4 per well in a 24-well plate
in DMEM containing 10% FCS. These cells were allowed to
attach for 24 hours, and the media were replaced with fresh media
containing either vehicle (dimethyl sulfoxide) or appropriate
concentrations of test compounds. After 36 hours of incubation
with either vehicle or compounds, cells were trypsinized and cell
viability was determined by the trypan blue exclusion assay using a
hemacytometer. For the XTT assay, cells were seeded into 96-well
cell culture plates at a density of 0.6610
4 per well. After the
appropriate treatment described above, cells were incubated with
0.1 mg/ml of 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(pheny-
lamino)carbonyl]-2H-tetrazolium hydroxide (XTT) for 4 hours
and then cell number was determined by the absorbance at
470 nm, which is proportional to the number of cells that
remained attached to the plate. GI50s were calculated as the
inhibitor concentration needed for 50% of vehicle-treated cell
growth. The appearance of apoptotic or necrotic cells was
determined by flow cytometric analysis of cells double stained
with Annexin V-FITC and propidium iodide (PI) [38]. Apoptotic
and necrotic cells were distinguished on the basis of double-
Table 3. Statistics of reflection data and structure
refinements.
PFKFB3?Fru-6-P?N4A PFKFB3?Fru-6-P?YN1
Space group P6522 P6522
Unit cell dimensions
a=b(A ˚) 101.70 102.78
c( A ˚) 258.61 260.10
Resolution range (A ˚) 61.6-2.4 50.4-3.3
No. reflections used 26,883 20,476
Completeness (%) 100.00 88.96
Redundancy 7.2 (2.6) 9.5 (2.2)




No. amino acids 443 441
No. protein atoms 3881 3637
No. hetero atoms 52 40
No. water molecules 192 -
r.m.s.d. from ideal
Bond lengths (A ˚) 0.021 -
Bond angles (deg.) 2.016 -
Dihedral angles (deg.) 20.9 -
Mean Bfactor
Protein atoms (A ˚2) 35.53 90.93
Hetero atoms (A ˚2) 48.23 106.73
Water atoms (A ˚2) 43.08 -
Rsym=gh(gj|Ih,j2,Ih.|/gIh,j), where h=set of Miller indices, j=set of
observations of reflection h,a n d,Ih.=the mean intensity.
Rcrys=gh||Fo,h|2|Fc,h||/gh|Fo,h|. Rfree was calculated using 10% of the complete
data set excluded from refinement. The numbers in parentheses represent
values from the highest resolution shell.
doi:10.1371/journal.pone.0024179.t003
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membrane-impermeable DNA stain. Floating and freshly trypsin-
ized cells were pooled, washed twice in binding buffer, and
processed following manufacturer’s instructions. The fluorescence
of samples were analyzed by flow cytometry (FACSCaliburH,
Becton Dickinson Immunocytometry, San Jose, CA) using the
CellQuest (BD Bioscience, Immunocytometry Systems, San Jose,
CA, USA) software.
For HeLa cell colony formation was determined by soft agar
assay. Cells (26103) were mixed in DMEM medium containing
0.35% agarose and varying concentrations of N4A or YN1. Then
the cell mixture was added on a layer of 0.6% concentration of
bottom agar in 24 well plates and allowed to grow for three weeks
at 37uCunder 5% CO2. Fresh medium containing the inhibitors or
vehicle (DMSO) was changed every four days. Colonies of 50 cells
or more were counted after three weeks. The experiments were
repeated at least five times.
Diffraction data collection and processing
Crystals were soaked with cryoprotectant solutions for 0.5 to
2 hours before cryogenic data collections. Depending on the
experimental aims, cryoprotectant solutions (a crystallization
reservoir solution enriched with 30% glycerol) were enriched with
0.3 mM of inhibitor. A soaked crystal was flash-frozen at 100 K
using an Oxford cryo-device and kept at the same temperature
during data collections. The diffraction data were collected at The
Northeastern Collaborative Access Team (NE-CAT) Beamline at
the Advanced Photon Source, Argonne National Laboratory,
Argonne, IL. The X-ray source wavelength was 0.9792 A ˚. The
data recorded on a ADSC Q315 detector were integrated,
merged, and scaled using XDS [39]. Statistics of the diffraction
data and structure refinement are summarized in Table 1. The
crystals belong to P6522 space group with similar cell dimensions.
Structure determination and refinement
The reduced data were formatted for the program suites of
CCP4 [40] and 10% of the data were marked for free R-factor
measurements in subsequent structure refinements. The search
model was built from the coordinates of the PFKFB3NFru-6-
PNEDTA complex structure (PDB accession code 2AXN) [29] by
stripping all the included ligand and solvent molecules to
determine the N4A complex structures of PFKFB3. The initial
model was determined using REFMAC within the CCP4 suit and
processed through iterated cycles of manual model rebuilding and
validation using the program COOT [40]. Binding of the ligands
was confirmed, referring to the |Fo|2|Fc| omit maps that were
generated, when Rcrys/Rfree reached 0.23/0.29 or below.
Referring to these maps, Fru-6-P, N4A or YN1 was incorporated
into the corresponding complex models. As summarized in
Table 3, the final model of the PFKFB3NFru-6-PNN4A complex
has Rcrys/Rfree of 0.215/0.262 using a total of 3881 scatterers,
including solvent molecules, against all available 26,883 reflections
in the resolution range of 61.6–2.4 A ˚. The structure contains a
total of 443 amino acid residues of the full-length protein of 520
residues. As in the PFKFB3NADPNEDTA complex, the C terminus
(residues 446–520) is mostly disordered.
The PFKFB3NFru-6-PNYN1 complex was built from N4A
complex through only rigid body and B-group refinement because
of resolution limit, resulting with Rfree/Rcrys of 0.243/0.250 using
a total of 3700 scatterers against all available 12,140 reflections in
the resolution range of 89.0–3.3 A ˚. The structure contains a total
of 448 amino acid residues of the full length protein of 520
residues. In the both structures, more than 89% of the residues are
in the most favored region, 9.5% in the additional region, and the
rest in the generously allowed region in the Ramachandran plots.
The structure refinement statistics are summarized in Table 3.
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